GlobeNewsWire
29 Sept 2026, 09:15 UTC · 7w ago
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Impact · against what's priced in
KURA receives a positive catalyst from preclinical data showing KO-7246 can regenerate pancreatic beta-cells in Type 1 and Type 2 diabetes models. The potential for disease-modifying therapy and synergy with GLP-1s like semaglutide expands the company's addressable market beyond its current oncology focus.
- KURA+0.70
No priced-in read yet





